

Topiramate (Topamax®)

This sheet is about exposure to topiramate in pregnancy and while breastfeeding. This information should not take the place of medical care and advice from your healthcare provider.

What is topiramate?

Topiramate is a medication used to prevent seizures and migraine headaches. It has also been used to treat alcoholism, eating disorders, tremors, obesity, diabetes, and psychiatric disorders such as bipolar disorder. Topiramate is sold under the brand names Topamax®, Trokendi XR®, Qudexy XR®. It is also part of a weight loss drug called Qysymia®.

Sometimes when people find out they are pregnant, they think about changing how they take their medication, or stopping their medication altogether. However, it is important to talk with your healthcare providers before making any changes to how you take this medication. Your healthcare providers can talk with you about the benefits of treating your condition and the risks of untreated illness during pregnancy.

I am taking topiramate, but I would like to stop taking it before becoming pregnant. How long does the drug stay in my body?

People eliminate medication at different rates. In healthy adults, it takes up to 5.25 days, on average, for most of the topiramate to be gone from the body.

I take topiramate. Can it make it harder for me to get pregnant?

Based on the studies reviewed, it is not known if topiramate can make it harder to get pregnant. Studies have found that the long-term use of seizure medications in people with a seizure disorder might be linked to irregular periods and trouble getting pregnant.

The use of topiramate at the same time as birth control medications may make the birth control less effective. Please discuss this with your healthcare provider if you take topiramate and want to take birth control medications.

Does taking topiramate increase the chance for miscarriage?

Miscarriage can occur in any pregnancy. Studies have not been done to see if topiramate increases the chance for miscarriage.

Does taking topiramate increase the chance of birth defects?

Every pregnancy starts out with a 3-5% chance of having a birth defect. This is called the background risk. Some studies suggest that topiramate use in the first trimester may increase the chance that a baby will be born with a cleft lip and/or a cleft palate (split lip or opening in the roof of the mouth). The chance for this to happen is expected to be 1 in 100 (1%) or less. Most children who are exposed to topiramate during pregnancy do not have a birth defect.

If you are taking topiramate, your healthcare provider may suggest you take a higher dose of folic acid for at least 3 months before getting pregnant to help lower the chance for certain birth defects. Talk with your healthcare provider to find out how much folic acid is right for you. More information about folic acid can be found in our fact sheet here:

<https://mothertobaby.org/fact-sheets/folic-acid/>.

Does taking topiramate in pregnancy increase the chance of other pregnancy-related problems?

Some studies suggest that topiramate can cause other pregnancy-related problems, such as preterm delivery (birth before week 37) or low birth weight (weighing less than 5 pounds, 8 ounces (2500 grams) at birth).

Does taking topiramate in pregnancy affect future behavior or learning for the child?

Based on the studies reviewed, it is not known if topiramate increases the chance for behavior or learning issues. One small study has suggested that taking topiramate during pregnancy might have an effect on learning and motor coordination. Another small study did not report problems in verbal abilities or IQ scores when testing children between the ages of 5 and 9 years. A larger study did not find an increased risk for poor early neurodevelopmental outcomes in babies exposed to topiramate during pregnancy.

Breastfeeding while taking topiramate:

Topiramate gets into breastmilk in small amounts. If you suspect the baby has any symptoms, such as diarrhea, drowsiness, irritability, or trouble gaining weight, contact the child's healthcare provider. Be sure to talk to your healthcare provider about all your breastfeeding questions.

If a male takes topiramate, could it affect fertility (ability to get partner pregnant) or increase the chance of birth defects?

Studies have not been done to see if topiramate could affect fertility or increase the chance of birth defects above the background risk. In general, exposures that fathers or sperm donors have are unlikely to increase the risks to a pregnancy. For more information, please see the MotherToBaby fact sheet Paternal Exposures at

<https://mothertobaby.org/fact-sheets/paternal-exposures-pregnancy/>.

Selected References:

- Afrman, JJ, et al. 2020. Therapeutic Drug Monitoring of Antiepileptic Drugs in Women with Epilepsy Before, During, and After Pregnancy. Clin Pharmacokinet. 59(4):427-45
- Alsaad AMS, et al. 2015. First trimester exposure to topiramate and the risk of oral clefts in the offspring: A systematic review and meta-analysis. Reprod Toxicol 53: 45-50.
- Blotière PO, et al. 2020. Risk of early neurodevelopmental outcomes associated with prenatal exposure to the antiepileptic drugs most commonly used during pregnancy: a French nationwide population-based cohort study. BMJ open. 10(6):e034829
- Blotière PO, et al. 2019. Risks of 23 specific malformations associated with prenatal exposure to 10 antiepileptic drugs. Neurology 93(2):e167-80.
- Bromley RL, et al. 2016. Cognition in school-age children exposed to levetiracetam, topiramate, or sodium valproate. Neurology. 87(18):1943-53.
- Committee on Drugs. 2001. The transfer of drugs and other chemicals into human milk. Pediatrics, 108(3), 776-789.
- Heinonen OP, Slone D, Shapiro S. Birth defects and drugs in pregnancy. Littleton, MA: John Wright-PSG, 1977a, pp 389, 391-392, 394, 443, 478, 497.
- Hernandez-Diaz S, et al, for the North American AED Pregnancy Registry. 2012. Comparative safety of antiepileptic drugs during pregnancy. Neurology; 78:1692-1699.
- Hernandez-Diaz S, et al. 2014. Association between topiramate and zonisamide use during pregnancy and low birth weight. Ob Gyn. 123(1): 21-28.
- Hernandez-Diaz S, et al. 2017. Fetal growth and premature delivery in pregnant women on antiepileptic drugs. Ann Neurol. 82(3):457-65.
- Hernandez-Diaz S, et al. 2018. Topiramate use early in pregnancy and the risk of oral clefts: a pregnancy cohort study. Neurology; 90(4):e342-51.
- Keni RR, et al. 2018. Teratogenicity of antiepileptic dual therapy: Dose-dependent, drug-specific, or both?. Neurology. 90(9); e790-6.
- Keni RR, et al. 2020. Anti-epileptic drug and folic acid usage during pregnancy, seizure and malformation outcomes: Changes over two decades in the Kerala Registry of Epilepsy and Pregnancy. Epilepsy Research; 159:106250.
- Ornoy A, et al. 2017. Antidepressants, antipsychotics, and mood stabilizers in pregnancy: what do we know and how should we treat pregnant women with depression. Birth defects research;109(12):933-56.
- Tomson T, et al. 2018. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. The Lancet Neurology;17(6):530-8.

- Vajda FJ, et al. 2016. Antiepileptic drug combinations not involving valproate and the risk of fetal malformations. *Epilepsia*. 57(7):1048-52.
- Veroniki AA, et al. 2017. Comparative safety of anti-epileptic drugs during pregnancy: a systematic review and network meta-analysis of congenital malformations and prenatal outcomes. *BMC medicine*. 15(1):95.
- Vajda FJ, et al. 2018. Antiepileptic drug polytherapy in pregnant women with epilepsy. *Acta Neurologica Scandinavica*; 138(2):115-21.
- Vajda FJ, et al. 2019. Antiepileptic drugs and foetal malformation: analysis of 20 years of data in a pregnancy register. *Seizure*; 65:6-11.
- Vajda FJ, et al. 2019. Preexisting illness, fetal malformation, and seizure control rates in pregnant women with epilepsy. *Epilepsy & Behavior*; 9:106481.
- Weston J, et al. 2016. Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. *Cochrane Database Syst Rev*. 11:Cd010224.